Small molecule · Modulator of estrogen receptor alpha (ESR1) and progesterone receptor (PGR) · developed by Bayer Healthcare Pharmaceuticals
Drospirenone/ethinyl estradiol is a combined oral contraceptive pairing the progestin drospirenone with the estrogen ethinyl estradiol. The combination suppresses the hypothalamic-pituitary system, inhibiting FSH and LH release and ovulation, and thickens cervical mucus. It is used to prevent pregnancy and to treat premenstrual dysphoric disorder and moderate acne in women choosing it for contraception.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of May 29, 2025). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06250205 | Phase 1 | Healthy Volunteers | Completed | NAMS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Healthy Volunteers
Updated Oct 25, 2026.